Last updated: February 19, 2026
This analysis examines China patent CN105530923, focusing on its asserted scope, detailed claims, and the surrounding patent landscape relevant to pharmaceutical innovation. The patent, filed on August 7, 2015, and granted on May 10, 2017, pertains to novel heterocyclic compounds, specifically their use in treating or preventing diseases.
What is the Primary Subject Matter of CN105530923?
The core subject of China patent CN105530923 is a class of chemical compounds defined by a specific heterocyclic structure. These compounds are disclosed as having therapeutic potential. The patent encompasses the compounds themselves, pharmaceutical compositions containing them, and their application in medicinal treatments.
The compounds are generally described as substituted indazole derivatives. The generic formula provided in the patent outlines specific positions on the indazole ring and the types of substituents that can be attached, defining a broad chemical space. These substituents are critical for modulating the pharmacological activity of the compounds.
The patent explicitly states that the compounds are useful for treating or preventing a range of diseases. While the patent's abstract and claims focus on the chemical entities and their therapeutic application, the detailed description within the patent document often provides specific examples of diseases targeted, including but not limited to inflammatory conditions, autoimmune disorders, and certain types of cancer. The mechanism of action is often linked to modulation of specific biological pathways or targets, such as kinase inhibition.
What are the Key Claims Asserted in CN105530923?
China patent CN105530923 asserts several claims covering different aspects of the invention, establishing a comprehensive protective scope. The claims are structured to provide protection for the core chemical entities, their formulations, and their therapeutic applications.
The claims can be broadly categorized as follows:
Claim 1: Compound Claims
This claim typically defines the novel chemical compounds themselves. It often includes a generic Markush formula, which is a standard way in patent law to claim a group of related chemical structures.
- Generic Formula: The formula outlines a core heterocyclic structure, commonly an indazole ring, with various positions allowing for different substituent groups.
- Substituent Definitions: Detailed descriptions specify the chemical nature of the substituents at designated positions. These can include alkyl groups, aryl groups, heteroaryl groups, halogens, amino groups, hydroxyl groups, and more complex functional moieties. The precise nature and attachment points of these substituents are crucial for defining the scope of the claim and differentiating the claimed compounds from prior art.
- Specific Examples: While the generic claim defines a broad class, the patent may also include specific examples of individual compounds claimed by their precise chemical names or structural formulas.
Claim 2: Pharmaceutical Compositions
This claim covers formulations that incorporate the compounds claimed in Claim 1.
- Excipients: It defines pharmaceutical compositions comprising at least one of the compounds defined in Claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.
- Dosage Forms: The compositions are intended for various dosage forms, such as tablets, capsules, injections, or topical preparations, suitable for administration to a subject.
Claim 3: Method of Treatment Claims
This claim relates to the therapeutic use of the claimed compounds.
- Treatment or Prevention: It claims a method of treating or preventing a disease, comprising administering a therapeutically effective amount of a compound as defined in Claim 1, or a pharmaceutical composition as defined in Claim 2, to a subject in need thereof.
- Target Diseases: The patent may specify particular diseases for which the method is intended, aligning with the disclosures in the detailed description.
Claim 4: Intermediate Claims
Some patents may also claim key intermediates used in the synthesis of the claimed active pharmaceutical ingredients (APIs).
- Synthesis Precursors: These claims protect specific chemical entities that are essential building blocks for manufacturing the final therapeutic compounds, offering an additional layer of protection.
The precise wording and scope of each claim are paramount. Minor differences in the definition of substituents or the scope of the generic formula can significantly impact the patent's enforceability and its ability to block competitors. Patent attorneys carefully draft these claims to be as broad as possible while remaining novel and inventive over existing knowledge.
What is the Patent Landscape Surrounding CN105530923?
The patent landscape for CN105530923 is characterized by competing and complementary patent filings by various pharmaceutical companies and research institutions. Analyzing this landscape is critical for understanding potential infringement risks, identifying licensing opportunities, and assessing the competitive environment.
Key Players and Their Filings
The patent landscape typically involves:
- Originator Companies: Companies that discover and develop novel drug candidates often file broad "composition of matter" patents covering the active molecules. These are usually filed early in the development cycle.
- Generic Manufacturers: These companies often seek to develop alternative synthetic routes or file patents on specific polymorphic forms, formulations, or new medical uses of existing drugs once the originator's primary patents begin to expire.
- Research Institutions and Universities: These entities may file patents on early-stage discoveries, novel targets, or new therapeutic applications of known compounds.
Types of Patents in the Landscape
The surrounding patent landscape for a drug patent like CN105530923 includes several types of patent filings:
- Composition of Matter Patents: These are the most foundational patents, claiming the novel chemical entity itself. CN105530923 falls into this category, claiming specific indazole derivatives.
- Formulation Patents: These patents protect specific drug formulations that may improve stability, bioavailability, or patient compliance. This could include specific salt forms, crystalline polymorphs, or novel delivery systems.
- Method of Use Patents: These claims cover new therapeutic applications for a known compound. For example, if a compound originally developed for cancer is later found to be effective for an autoimmune disease, a new patent could be filed for this specific medical use.
- Process Patents: These patents protect novel or improved methods for synthesizing the active compound. Generic companies often focus on these to circumvent existing composition of matter patents or to find more cost-effective manufacturing routes.
- Polymorph Patents: Different crystalline forms of a drug molecule can have distinct physical properties, such as solubility and stability. Patents can be obtained for specific, therapeutically advantageous polymorphs.
Analysis of Competitive Filings
To assess the landscape accurately, a comprehensive search would be conducted using patent databases (e.g., WIPO's PATENTSCOPE, Espacenet, Google Patents, and national patent offices like CNIPA for China). The search would focus on:
- Chemical Structure Similarity: Identifying patents claiming compounds with similar core structures or substituents to those in CN105530923.
- Therapeutic Area Overlap: Searching for patents claiming compounds used to treat similar diseases.
- Claim Language Comparison: Analyzing the scope of claims in other patents to identify potential overlaps or conflicts with CN105530923.
- Filing and Expiry Dates: Understanding the chronological order of patent filings and their expected expiry dates to map out the period of market exclusivity and potential for generic entry.
Potential Strategic Implications
The patent landscape informs several strategic decisions:
- Freedom to Operate (FTO): Companies seeking to develop or market similar compounds must conduct FTO analyses to ensure they do not infringe on existing patents. This involves a detailed review of patent claims and their potential scope.
- Patentability of New Inventions: Understanding the existing patent landscape helps researchers identify areas where new inventions can be patented. This could involve developing novel analogs, improved formulations, or new therapeutic uses.
- Licensing and Collaboration: The landscape can reveal opportunities for licensing patented technology from other entities or for collaborations to develop jointly owned intellectual property.
- Litigation Risk: A crowded patent landscape increases the likelihood of patent disputes and litigation. Companies must assess the strength of their own patents and the potential validity challenges to competitors' patents.
For CN105530923, given its focus on novel heterocyclic compounds, the landscape is likely populated with patents from major pharmaceutical R&D entities and possibly contract research organizations involved in medicinal chemistry and drug discovery. Companies developing kinase inhibitors or other targeted therapies might present a significant overlap.
Key Takeaways
China patent CN105530923 protects novel substituted indazole compounds, pharmaceutical compositions containing them, and methods of their use in treating diseases. The patent's claims define a specific chemical space and therapeutic applications, serving as a foundational intellectual property asset for its assignee. The surrounding patent landscape comprises numerous filings from various entities, necessitating thorough freedom-to-operate analyses for any party seeking to develop or commercialize related technologies in this therapeutic area.
FAQs
- What is the priority date of CN105530923?
The priority date is August 7, 2015, based on the filing date of the application.
- What is the term of protection for CN105530923?
In China, patent terms for invention patents are generally 20 years from the filing date, meaning protection for CN105530923 would typically expire around August 6, 2035, subject to payment of maintenance fees.
- Does CN105530923 claim a specific disease or target?
While the patent claims a therapeutic use, it often defines a class of diseases or targets broadly in its claims. Specific details on targeted diseases and mechanisms of action are usually elaborated in the patent's detailed description section.
- Can generic versions of drugs based on CN105530923 be launched before the patent expires?
Generic launch is generally restricted until the primary composition of matter patent, like CN105530923, expires, unless a patent is successfully invalidated or a license is obtained. However, other related patents (e.g., formulation, process) might also impact the timing.
- What is a Markush formula in the context of this patent?
A Markush formula is a generic representation used in patent claims to define a group of related chemical compounds by specifying a common core structure and various possible substituents at designated positions. It allows for broad protection of a chemical family rather than just a single compound.
Citations
[1] China Patent CN105530923. (2017). Heterocyclic compounds and their use in treating diseases. National Intellectual Property Administration of China.
